DERMATA THERAPEUTICS INC

Dermata Therapeutics shares tumble 8% as the biotech files a new prospectus; explore the company’s 2026 outlook, risk profile, and peer context.

Dermata Therapeutics’ shares dropped 8% amid a new prospectus for a potential 6.9 M share resale, reflecting investor caution and a shift to a direct‑to‑consumer skincare model.

Dermata Therapeutics (DRMA) hits $0.83 as it clears SEC approval for a public offering, amid a volatile small‑cap biotech market.

Dermata Therapeutics’ flat stock shows a sharp 25% fall—why investors doubt its clinical pipeline and how a strategic shift could revive its biotech promise.